Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413056
Status:
COMPLETED
Last Update Posted:
2024-05-16
First Post:
2024-03-11
Brief Title:
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
Sponsor:
Ain Shams University
Organization:
Ain Shams University
Study Overview
Official Title:
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates A Randomized Control Trial
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The incidence of fungal infection has increased dramatically over the past few decadesThis is due to increase in survival rates of preterm neonates advances in medical technology and drug therapy broad spectrum antibiotics and parenteral nutrition The resistance to antifungal agents has increased This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture
Detailed Description:
Neonatal candidiasis is associated with significant mortality and morbidity and high rates of neuro-developmental impairment on follow up Prevalence of invasive fungal infection IFI has increased in neonates during the last two decades due to increased survival rate even in the extremely premature neonates Candida albicans and Candida parapsilosis are responsible for the majority of candidiasis in the neonatal intensive care unit NICU According to the European Society for Clinical Microbiology and Infectious Diseases ESCMIDguidelines published in 2012 Micafungin amphotericin B deoxycholate and fluconazole are recommended as first line treatment of invasive candidiasis in neonates Currently fluconazole and micafungin are among the most frequently used antifungal agents for the treatment of neonatal invasive candidiasis High dose of micafungin 8 to 15 mgkgday can be used with neonates and infant with invasive candidiasis In this study we will explore the effectiveness and safety of micafungin for treatment of candidiasis after fluconazole for preterm neonates with invasive fungal infection and to compare it with amphotericin B
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None